Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.60
Bid: 2.50
Ask: 2.70
Change: -0.05 (-1.89%)
Spread: 0.20 (8.00%)
Open: 2.65
High: 2.65
Low: 2.60
Prev. Close: 2.65
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Arecor Therapeutics wins patent approval in US

Wed, 23rd Mar 2022 20:53

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Hydrogen Utopia International PLC - London-based company specialising in turning non-recyclable mixed waste plastic into carbon-free fuels - Says it believes that building new waste plastic to energy plants could be "significant" in allowing local communities across Europe to lessen the impacts of the gas and energy supply crisis and the anticipated market changes brought about by ongoing sanctions against Russia and the reluctance to rely upon it as an energy supplier in the future.

----------

ValiRx PLC - Nuneaton, England-based drug development company - Reports it is progressing towards the completion of its proposed sub-licence of VAL201 to TheoremRx Inc. VAL201's primary indication is for prostate cancer, with potential further research & development in breast and ovarian cancer. Company says TheoremRx continues to make good progress with its financing but notes that current global macro-economic events have impacted the timelines. First payments to ValiRx are expected on or before the end of June.

----------

Arecor Therapeutics PLC - Essex, England-based biopharmaceutical company - Wins patent grant from US Patent & Trademark Office protecting novel formulations of the group's insulin products, AT247 and AT278. Chief Scientific Officer Jan Jezek says: "This recently granted US patent, the first within the group's comprehensive insulin IP strategy, is a significant milestone, and we will continue to strengthen our IP portfolio with additional patent applications already in progress."

----------

GENinCode PLC - Manchester-based genetic testing company - Collaborates with Indiana University School of Medicine on a study using its Cardio inCode-SCORE for the risk assessment of patients for onset of atherosclerotic cardiovascular disease.

----------

88 Energy Ltd - oil exploration company focused on Alaska - Reaches total depth of 7,334 feet at Merlin-2 well and ceases drilling. Company says all three target reservoirs at the well were penetrated with elevated gas readings. Adds observations of cutting samples have revealed oil shows over all targets. Wireline logging is due to commence shortly.

----------

i(x) Net Zero PLC - Jersey-based investment company focused on sustainability - Says portfolio company Context Labs has secures a multi-year partnership with energy company Williams Co Inc. Partnership for the deployment of its Immutably-based Decarbonization as a Service platform. The deployment of the enterprise data fabric solution will facilitate Williams' energy transition, i(x) explains.

----------

All Star Minerals PLC - Haywards Heath, England-based mining services investor - Appoints Jason Brewer as chief executive officer. Current CEO Ian Harebottle reverts to the position of non-executive director with immediate effect. Says restructuring has been driven by "recent developments in Europe".

----------

Panther Metals PLC - mineral exploration company focused on Canada - Notes announcement of Panther Metals Ltd, in which it has 37% holding, detailing "significant" reverse circulation drilling sample assay results. Results from the Coglia nickel cobalt project in Western Australia include: 21 metres at 1.34% nickel from 72 metres and 10 metres at 1.3% nickel from 62 metres. 18 of the 26 holes assayed return results above 0.5% nickel and 500 parts per million of copper. Once drilling is complete at Coglia the drill rig will move to the Eight Foot Well gold prospect, the company adds.

----------

Cohort PLC - Reading, England-based technology company - Says its German subsidiary ELAC Sonar has been awarded a contract to supply hydroacoustic equipment by Fassmer Shipyard, on behalf of the Federal Office of Bundeswehr Equipment, Information Technology and In-Service Support. Contract is worth EUR4 million and is expected to complete in the final quarter of 2023.

----------

Tern PLC - London-based investor focused on the internet of things - Notes that Wyld Networks AB has received a purchase order for its Wyld Connect internet of things module from an unnamed Brazilian company in the forestry sector. Tern holds 59% of Wyld Networks.

----------

Capital Metals PLC - London-based mineral sands explorer - Says IHC Mining is nearing the completion of the development study for the Eastern Minerals project in Sri Lanka. Capital Metals expects the final report by mid-April. Adds that drill samples from the project are continuing to be assayed by an independent laboratory but warns of backlogs. Company working with Sri Lankan government to secure industrial mining license but says timeline is beyond their control. Discussion regarding offtake and strategic party agreements continue.

----------

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
15 Nov 2013 07:53

AIM IN BRIEF: Quindell And ValiRx Placings; Noricum Gold Positive Results

Read more
24 Oct 2013 15:48

ValiRx Anti-Cancer Treatment Advances To Phase 2 Of Clinical Trial

Read more
3 Oct 2013 11:39

UK WINNERS & LOSERS: Phorm Jumps; Supermarkets Rebound

Read more
3 Oct 2013 08:08

ValiRx Cancer Treatment Files Escalation Study

Read more
5 Sep 2013 11:44

ValiRX reports encouraging progress despite losses

ValiRx, a biopharmaceutial company with a focus on the treatment of cancer, said while losses had widened in the first half it had made "excellent" advances in its clinical and pre-clinical development pipeline. It reiterated that it expected results from the first stage of clinical trials for its

Read more
5 Sep 2013 09:20

ValiRx Losses Widen But Says Compounds Progressing In Trials

Read more
25 Apr 2013 10:02

ValiRx granted patent in Australia for VAL201 targeting cancer

ValiRx has been granted a patent for its lead therapeutic compound VAL201 for the treatment of breast, prostate, breast and ovarian cancer in Australia. The cancer diagnostics company said VAL201 has shown efficacy in prostate, breast and ovarian cancer as well as addressing endometriosis or hormon

Read more
2 Apr 2013 08:41

ValiRx to present at key Cancer Conference

Shares in life science company ValiRx rose on Tuesday morning after the AIM-listed company announced that it would be presenting at the American Association for Cancer Research Conference this year. The conference, which was attended by approximately 17,000 delegates last year, is seen as a key eve

Read more
21 Feb 2013 13:17

ValiRx appoints COO to help build portfolio

Biotech firm ValiRx has appointed a Chief Operating Officer to assist in building and adding value to its portfolio of technologies and to coordinate ValiRx's commercial strategy. Samual Ogunsalu has a background in Microbiology and Biochemical engineering and has 15 years' experience in the identi

Read more
22 Nov 2012 15:56

Small cap round-up: InterQuest, ValiRx, Aeorema Comms

InterQuest has warned that trading during the summer, traditionally its strongest period, has been sluggish. As a result underlying earnings before interest, tax, depreciation and amortisation (EBITDA) will be in the region of 2.2m pounds. This does not include an exceptional credit of about 0.85m p

Read more
11 Oct 2012 09:50

Contract wins round-up: LO-Q, Motive TV, Plexus ...

Lo-Q has announced its second contract win of the week, as an unnamed major US theme park operator has signed up to use the firm's virtual queueing system at two sites in the US. Revenue associated with the agreement is expected to scale gradually, over time. In addition, the deal grants that Lo-Q's

Read more
29 May 2012 08:37

Small cap round-up: ValiRx, Transense, Sweett

Shares in ValiRx, the life sciences firm, leapt almost 40% on Tuesday after it said independent trials had confirmed the effectiveness of its prostate cancer drug VAL201. The firm said the "significant and substantively important findings" showed its drug reduced the spread of secondary tumours by u

Read more
15 May 2012 13:12

Small caps round-up: Cello, DDD, Kewill...

Marketing firm Cello Group has reported good trading during the first three months of the year, reflecting 'the strong pipeline of work secured at the end of 2011 and a solid flow of bookings'. The research and consulting division was a strong performer, while the group's focus on the pharmaceutic

Read more
27 Apr 2012 14:20

Small caps round-up: James Cropper, ValiRx, ReNeuron

James Cropper, a specialist paper and materials group, has said that pre-execptional profit before tax is set to be in line with market expectations. The company also said its previously announced restructuring process will reduce the size of the UK workforce by eight per cent during the current yea

Read more
2 Apr 2012 13:36

Small caps round-up: Rock Solid, ValiRx, InternetQ, Quindell

Rock Solid Images, an oil equipment, services and distribution firm, has received an offer from Thalassa Holdings to acquire up to 25.89 per cent of the company for 0.48p per share in cash. Rock Solid is concerned that Thalassa has provided no evidence that they will bring any "added economic or ind

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.